Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Hematology · Chronic Myeloid Leukemia

What Does 10% to 19% Blasts Mean for Ph+ CML Patients?

At a Glance

In Philadelphia-positive CML, 10% to 19% blasts is concerning but does not automatically mean blast phase. WHO and ICC systems may label this range differently, so doctors use blood or marrow findings, PCR trends, mutation testing, and treatment history to plan next steps.

In this answer

4 sections

01

How Blasts Are Measured

02

The “Rulebook” Confusion: Why Labels Vary

03

Other Warning Signs That Matter

04

Next Steps and Treatment Planning

  • It means the percentage of blasts (immature cells) in your blood or bone marrow is higher than the standard target for the chronic phase (which is strictly under 10%) [1][2]. This is a concerning finding that requires prompt review by your hematologist.
  • It does NOT mean you are automatically in the “blast phase” [3].
  • The exact label depends on the medical classification system your doctor uses (such as WHO or ICC) and whether this result was found in your blood or bone marrow, along with other test results [1].
  • Do not stop, switch, or change the dose of your current targeted therapy (TKI) without explicit instructions from your care team.

How Blasts Are Measured

Blasts are immature white blood cells. In healthy individuals, blasts stay in the bone marrow until they mature. In CML, they can multiply rapidly and spill into the bloodstream. They are counted using an expert manual review (a differential) of your sample:

  • Peripheral blood differential: A cell count from a standard blood draw [4]. A high blast count here can sometimes be enough to signal disease progression.
  • Bone marrow aspirate: A sample of the liquid portion of your bone marrow [4]. This is usually recommended to fully evaluate the disease.

If the liquid marrow sample is inadequate or shows scarring (marrow fibrosis), doctors may use a solid core biopsy to assess the marrow’s architecture. They may also use flow cytometry (a laser-based test) to identify the specific type and lineage of the blasts (e.g., myeloid vs. lymphoid cells) [5][6].

The “Rulebook” Confusion: Why Labels Vary

A 10% to 19% blast count sits in an intermediate zone. Because hematology guidelines have evolved, the exact name your doctor uses will depend on which system they follow [1][3]:

Classification System How 10% to 19% Blasts Might Be Labeled Blast Phase Threshold
World Health Organization (WHO) 2022 High-Risk Chronic Phase (WHO 2022 removed the “accelerated phase” entirely) [7] 20% or more blasts [3]
International Consensus Classification (ICC) 2022 Accelerated Phase (ICC defines this phase using 10%–19% blasts in blood or marrow) [8][9] 20% or more blasts
Historical ELN Criteria Accelerated Phase (older guidelines often defined this phase using 15%–29% blasts) [1] 30% or more blasts

Regardless of the label, this blast percentage means your medical team needs to do a comprehensive evaluation to understand why the leukemia is changing.

Other Warning Signs That Matter

Doctors look at the full picture, not just the blast count. Other signs that the leukemia might be changing include [1][10]:

  • Basophilia: A persistent level of basophils (another type of white blood cell) at 20% or higher [1][9].
  • Platelet Abnormalities: A persistent drop in platelets (below 100 x 10^9/L) that is not caused by your medication [9][11].
  • Additional Chromosomal Abnormalities (ACAs): Also known as clonal evolution, this means the leukemia cells have acquired extra chromosome changes (like an extra chromosome 8) beyond the original Philadelphia chromosome [12]. Certain high-risk ACAs can make the disease harder to treat [13]. (This is different from gene mutations, discussed below.)
  • Physical Symptoms: Symptoms like unexplained fever, worsening fatigue, bone pain, weight loss, or an enlarging spleen (feeling full quickly) can sometimes occur [14][15]. However, these symptoms are non-specific, and significant lab changes can happen without any new physical symptoms.
    (Note: Seek emergency care immediately if you experience severe shortness of breath, significant bleeding, high fever, or confusion.)

Next Steps and Treatment Planning

A single 10% to 19% blast result is a signal to contact your hematology team promptly—it is not necessarily an emergency room visit unless you have the severe symptoms mentioned above.

Your doctor will likely order a broader workup:

  1. Repeat Testing and PCR Trends: Looking at the trend in your quantitative BCR::ABL1 PCR levels to see how the disease is behaving over time [16].
  2. Mutation Testing: A BCR::ABL1 kinase-domain mutation test checks for specific gene changes (like the T315I mutation) that might make the leukemia resistant to your current targeted therapy [17][18].
  3. Evaluating Options: Depending on your prior treatments, mutation results, cardiovascular health, and specific blast type, your doctor might discuss:
    • Adjusting your TKI dose or switching to a different TKI (such as ponatinib or asciminib, if appropriate for your health profile) [19].
    • Adding other therapies, particularly if true advanced disease is confirmed.
    • An early consultation with a stem cell transplant specialist [20][21]. An allogeneic stem cell transplant (replacing your bone marrow with healthy cells from a donor) is not inevitable for everyone with 10%–19% blasts, but consulting early helps you plan.

Common questions in this guide

Does a 10% to 19% blast count mean my CML is already in blast phase?
Not necessarily. Under the 2022 WHO system, 10% to 19% blasts may be called high-risk chronic-phase CML, while the 2022 ICC may call it accelerated phase; both use 20% or more blasts as the blast-phase threshold. Your hematologist also considers whether the blasts are in blood or marrow and reviews other results.
How do doctors measure the blast percentage in CML?
Blasts are counted during an expert manual review of a blood or bone marrow sample. A peripheral-blood differential uses a blood draw, while a bone-marrow aspirate examines the liquid marrow; a core biopsy may be added if the sample is inadequate or the marrow is scarred. Flow cytometry can help identify whether the blasts are myeloid or lymphoid.
What other findings can make a 10% to 19% blast result more concerning?
Doctors also look for persistent basophils at 20% or higher, a medication-unrelated platelet count below 100 x 10^9/L, and additional chromosome changes called clonal evolution. They review trends in BCR::ABL1 PCR and symptoms such as fever, worsening fatigue, bone pain, weight loss, or an enlarging spleen. These findings are interpreted together rather than in isolation.
What tests might I need after a 10% to 19% blast result?
Your hematology team may repeat blood and bone marrow testing and review quantitative BCR::ABL1 PCR levels over time. They may order a BCR::ABL1 kinase-domain mutation test and use flow cytometry or chromosome testing to characterize the blasts and look for treatment resistance or additional chromosome changes. The exact workup depends on your prior results and treatment history.
Will a 10% to 19% blast count automatically mean I need a stem cell transplant?
No. An allogeneic stem cell transplant is not inevitable for everyone with this result, but an early consultation with a transplant specialist may help you understand and prepare for possible options. Decisions depend on the disease classification, blast type, mutation and treatment results, previous therapies, and overall health.
Should I stop or change my TKI after seeing this result?
Do not stop, switch, or change the dose of a tyrosine kinase inhibitor unless your care team specifically tells you to do so. Contact your hematology team promptly so they can review the result and your medication use. Seek emergency care for severe shortness of breath, significant bleeding, high fever, or confusion.

Related questions

What Happens If CML Misses 3-, 6-, or 12-Month Milestones? What Lifestyle Advice Applies During CML TKI Treatment? What Does an Undetectable BCR::ABL1 PCR Result Mean? What Are the WHO, ICC, and ELN CML Phase Definitions? What Drug and Food Interactions Affect CML TKI Treatment?
Show more
How Often Are CML PCR and CBC Tests Done After a TKI? How Do BCR::ABL1 Transcripts Affect CML Monitoring? How Does CML Progress from Chronic to Blast Phase? How Common Is Ph+ CML and What Age Is It Diagnosed? How Is Ph-Positive CML Different From Other Blood Cancers? What Does the ELTS Risk Score Mean in Ph+ CML Patients? What Is Life Expectancy for Adults With Ph+ CML Today? What Tests Confirm Philadelphia-Positive CML and Its Phase? How Do Health Conditions Affect First-Line CML TKI Choice? Why Do My CML PCR Results Change When I Feel Fine? Can Ph-Positive CML Cause Leukostasis Without Symptoms? How Is a Rising BCR::ABL1 in CML Checked for TKI Resistance? How Do Doctors Distinguish Ph+ CML From Ph+ ALL and MPNs? What Should I Do About a Rising BCR::ABL1 PCR in CML?

Get notified when new evidence is published on Philadelphia-positive myelogenous leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Chronic Myeloid Leukemia: A Review.

    Jabbour E, Kantarjian H

    JAMA 2025; (333(18)):1618-1629 doi:10.1001/jama.2025.0220.

    PMID: 40094679
  2. 2

    Uncommon phenotypes of BCR::ABL1-positive chronic myelogenous leukemia.

    Jajosky AN, Lichtman MA

    Haematologica 2025; (110(9)):1912-1920 doi:10.3324/haematol.2025.287792.

    PMID: 40371899
  3. 3

    Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations.

    Atallah E, Deininger M

    Drugs 2025; (85(1)):41-50 doi:10.1007/s40265-024-02108-2.

    PMID: 39638957
  4. 4

    CML with Megakaryocytic Blast Crisis: Report of 3 Cases.

    Khemka R, Gupta M, Jena NK

    Pathology oncology research : POR 2019; (25(3)):1253-1258 doi:10.1007/s12253-018-0484-7.

    PMID: 30357754
  5. 5

    Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value.

    Hidalgo-Lόpez JE, Kanagal-Shamanna R, Quesada AE, et al.

    Cancer 2018; (124(19)):3849-3855 doi:10.1002/cncr.31663.

    PMID: 30321462
  6. 6

    The importance of bone marrow biopsy for chronic myeloid leukemia classification-a case report.

    Gonçalves NV, Filho HLAS, de Magalhães Gomes JPC, et al.

    Journal of hematopathology 2026; (19(1)).

    PMID: 41748895
  7. 7

    Impact of the changes in chronic myeloid leukemia classification proposed by the 2022 World Health Organization: a single-center Brazilian study.

    Emiliano EG, Santos GEAA, Miranda ECM, et al.

    Hematology, transfusion and cell therapy 2026; (48(3)):106470 doi:10.1016/j.htct.2026.106470.

    PMID: 42142415
  8. 8

    International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms.

    Gianelli U, Thiele J, Orazi A, et al.

    Virchows Archiv : an international journal of pathology 2023; (482(1)):53-68 doi:10.1007/s00428-022-03480-8.

    PMID: 36580136
  9. 9

    The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia.

    Ohanian M, Kantarjian HM, Shoukier M, et al.

    American journal of hematology 2020; (95(10)):1127-1134 doi:10.1002/ajh.25907.

    PMID: 32557828
  10. 10

    Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.

    Lauseker M, Bachl K, Turkina A, et al.

    American journal of hematology 2019; (94(11)):1236-1243 doi:10.1002/ajh.25628.

    PMID: 31456269
  11. 11

    Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase.

    Furtado VF, Santos GR, de Carvalho DS, et al.

    Revista brasileira de hematologia e hemoterapia 2015; (37(5)):341-7.

    PMID: 26408370
  12. 12

    Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

    Wang W, Cortes JE, Tang G, et al.

    Blood 2016; (127(22)):2742-50 doi:10.1182/blood-2016-01-690230.

    PMID: 27006386
  13. 13

    High-risk additional chromosomal abnormalities at low blast counts herald death by CML.

    Hehlmann R, Voskanyan A, Lauseker M, et al.

    Leukemia 2020; (34(8)):2074-2086 doi:10.1038/s41375-020-0826-9.

    PMID: 32382082
  14. 14

    [Pre-therapeutic and evolutive characteristics of patients suffering from chronic myeloid leukemia, in Abidjan, Ivory Coast].

    Silué DA, Kouakou B, Nanho CD, et al.

    Bulletin du cancer 2019; (106(6)):550-559 doi:10.1016/j.bulcan.2019.03.013.

    PMID: 31088680
  15. 15

    Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation at a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional study.

    Urgessa F, Lengiso B, Tsegaye A, et al.

    BMC cancer 2024; (24(1)):530 doi:10.1186/s12885-024-12282-x.

    PMID: 38664756
  16. 16

    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

    Hochhaus A, Baccarani M, Silver RT, et al.

    Leukemia 2020; (34(4)):966-984 doi:10.1038/s41375-020-0776-2.

    PMID: 32127639
  17. 17

    Resistance mutations in CML and how we approach them.

    Soverini S

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):469-475 doi:10.1182/hematology.2023000447.

    PMID: 38066920
  18. 18

    [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].

    Cayuela JM, Chomel JC, Coiteux V, et al.

    Bulletin du cancer 2020; (107(1)):113-128 doi:10.1016/j.bulcan.2019.05.011.

    PMID: 31353136
  19. 19

    An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.

    Short NJ, Senapati J, Jabbour E

    Current hematologic malignancy reports 2023; (18(6)):234-242 doi:10.1007/s11899-023-00709-4.

    PMID: 37651057
  20. 20

    Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.

    Jabbour E, Kantarjian H

    American journal of hematology 2024; (99(11)):2191-2212 doi:10.1002/ajh.27443.

    PMID: 39093014
  21. 21

    Transplantation in CML in the TKI era: who, when, and how?

    Niederwieser C, Kröger N

    Hematology. American Society of Hematology. Education Program 2022; (2022(1)):114-122 doi:10.1182/hematology.2022000329.

    PMID: 36485123

This page explains how a 10% to 19% blast count may be classified in Philadelphia-positive CML for informational purposes only and does not constitute medical advice. Your hematologist should interpret your blood or marrow results, symptoms, and other tests with you.